First-in-class humanized FSH blocking antibody targets bone and fat.
Center for Clinical and Translational Research, Maine Medical Center Research Institute
Proceedings of the National Academy of Sciences of the United States of America
Antibodies, Blocking, Immunoglobulin Isotypes, Bone and Bones, Follicle Stimulating Hormone
Blocking the action of FSH genetically or pharmacologically in mice reduces body fat, lowers serum cholesterol, and increases bone mass, making an anti-FSH agent a potential therapeutic for three global epidemics: obesity, osteoporosis, and hypercholesterolemia. Here, we report the generation, structure, and function of a first-in-class, fully humanized, epitope-specific FSH blocking antibody with a
Gera, Sakshi; Sant, Damini; Haider, Shozeb; Korkmaz, Funda; Kuo, Tan-Chun; Mathew, Mehr; Perez-Pena, Helena; Xie, Honglin; Chen, Hao; Batista, Rogerio; Ma, Kejun; Cheng, Zhen; Hadelia, Elina; Robinson, Cemre; Macdonald, Anne; Miyashita, Sari; Williams, Anthony; Jebian, Gregory; Miyashita, Hirotaka; Gumerova, Anisa; Ievleva, Kseniia; Smith, Pinar; He, Jiahuan; Ryu, Vitaly; DeMambro, Victoria; Quinn, Matthew A; Meseck, Marcia; Kim, Se-Min; Kumar, T Rajendra; Iqbal, Jameel; New, Maria I; Lizneva, Daria; Rosen, Clifford J; Hsueh, Aaron J; Yuen, Tony; and Zaidi, Mone, "First-in-class humanized FSH blocking antibody targets bone and fat." (2020). Maine Medical Center. 1995.